Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Phathom Pharmaceuticals (PHAT) has appointed Ted Schroeder to its Board of Directors. Schroeder brings over 30 years of experience leading biopharmaceutical companies, with expertise in building commercial organizations, launching new therapies, and guiding companies through strategic milestones.
Board Chairman Michael Cola highlighted Schroeder's appointment comes at a pivotal period for Phathom, particularly as the company focuses on unlocking the full potential of VOQUEZNA®. Schroeder's operational and commercial expertise is expected to support Phathom's commercial momentum in delivering first-in-class therapies for gastrointestinal diseases.
Phathom Pharmaceuticals (PHAT) ha nominato Ted Schroeder nel suo Consiglio di Amministrazione. Schroeder vanta oltre 30 anni di esperienza nella guida di aziende biofarmaceutiche, con competenze nella creazione di organizzazioni commerciali, nel lancio di nuove terapie e nell’accompagnare le aziende attraverso tappe strategiche fondamentali.
Il Presidente del Consiglio, Michael Cola, ha sottolineato che la nomina di Schroeder arriva in un momento cruciale per Phathom, soprattutto mentre l’azienda si concentra sullo sfruttare appieno il potenziale di VOQUEZNA®. L’esperienza operativa e commerciale di Schroeder è destinata a sostenere lo slancio commerciale di Phathom nel fornire terapie innovative per le malattie gastrointestinali.
Phathom Pharmaceuticals (PHAT) ha nombrado a Ted Schroeder en su Junta Directiva. Schroeder aporta más de 30 años de experiencia liderando empresas biofarmacéuticas, con especialización en la creación de organizaciones comerciales, el lanzamiento de nuevas terapias y la orientación de compañías a través de hitos estratégicos.
El presidente del consejo, Michael Cola, destacó que el nombramiento de Schroeder llega en un momento clave para Phathom, especialmente mientras la empresa se enfoca en desbloquear todo el potencial de VOQUEZNA®. Se espera que la experiencia operativa y comercial de Schroeder respalde el impulso comercial de Phathom para ofrecer terapias innovadoras para enfermedades gastrointestinales.
Phathom Pharmaceuticals (PHAT)가 테드 슈로더를 이사회 멤버로 임명했습니다. 슈로더는 30년 이상의 바이오제약 업계 경력을 보유하고 있으며, 상업 조직 구축, 신약 출시, 전략적 이정표 달성을 이끄는 데 전문성을 갖추고 있습니다.
이사회 의장 마이클 콜라는 슈로더의 임명이 중요한 시기에 이루어졌다고 강조했으며, 특히 회사가 VOQUEZNA®의 잠재력을 최대한 발휘하는 데 집중하는 시점이라고 밝혔습니다. 슈로더의 운영 및 상업적 전문성은 위장 질환을 위한 혁신적인 치료제 제공에 있어 Phathom의 상업적 추진력을 지원할 것으로 기대됩니다.
Phathom Pharmaceuticals (PHAT) a nommé Ted Schroeder au sein de son Conseil d’Administration. Schroeder apporte plus de 30 ans d’expérience dans la direction d’entreprises biopharmaceutiques, avec une expertise dans la création d’organisations commerciales, le lancement de nouvelles thérapies et l’accompagnement des entreprises à travers des étapes stratégiques clés.
Le président du conseil, Michael Cola, a souligné que la nomination de Schroeder intervient à un moment crucial pour Phathom, notamment alors que l’entreprise se concentre sur la pleine exploitation du potentiel de VOQUEZNA®. L’expertise opérationnelle et commerciale de Schroeder devrait soutenir la dynamique commerciale de Phathom dans la fourniture de thérapies innovantes pour les maladies gastro-intestinales.
Phathom Pharmaceuticals (PHAT) hat Ted Schroeder in den Vorstand berufen. Schroeder bringt über 30 Jahre Erfahrung in der Führung von biopharmazeutischen Unternehmen mit, mit Expertise im Aufbau von Vertriebsorganisationen, der Markteinführung neuer Therapien und der Begleitung von Unternehmen durch strategische Meilensteine.
Der Vorstandsvorsitzende Michael Cola betonte, dass Schroeders Berufung in einer entscheidenden Phase für Phathom erfolgt, insbesondere da das Unternehmen darauf abzielt, das volle Potenzial von VOQUEZNA® zu erschließen. Schroeders operative und kommerzielle Expertise soll Phathoms kommerziellen Schwung bei der Bereitstellung erstklassiger Therapien für gastrointestinale Erkrankungen unterstützen.
- Addition of seasoned board member with 30+ years of biopharmaceutical leadership experience
- Strategic expertise in commercial scaling and therapy launches
- Strengthened oversight for VOQUEZNA commercialization
- None.
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors.
Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions.
“We are pleased to welcome Ted to the Phathom Board during a pivotal period for the company,” said Michael Cola, Chairman of the Board, Phathom Pharmaceuticals. “Ted is a seasoned biopharma leader with a strong history of developing and commercializing innovative treatments, scaling growth-focused organizations, and creating shareholder value. As Phathom continues to unlock the full potential of VOQUEZNA®, Ted’s deep operational and commercial expertise will be an important asset. We look forward to his insights and partnership as we work to accelerate our commercial momentum and deliver our first-in-class therapies to patients in need.”
About Ted Schroeder
Mr. Schroeder served as Chief Executive Officer of Nabriva Therapeutics from 2018 to 2023 and as a director until March 2025, following Nabriva’s acquisition of Zavante Therapeutics, where he was co-founder, President, and CEO. Prior to that, he co-founded Cadence Pharmaceuticals and served as President and CEO until its
Mr. Schroeder currently serves on the Board of Directors of Cidara Therapeutics (Nasdaq: CDTX) and has previously served on the boards of several public and private life sciences companies, including Otonomy, Collegium Pharmaceutical, Hyperion Therapeutics, Incline Therapeutics, and Trius Therapeutics. He is also a former Chairman of Biocom California and the Antimicrobials Working Group. In 2014, he was named EY Entrepreneur of the Year for the San Diego region and was recognized as a national finalist.
He holds a B.S. in Management from Rutgers University.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved.
VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
Who is the new board member appointed to Phathom Pharmaceuticals (PHAT)?
What experience does Ted Schroeder bring to Phathom Pharmaceuticals' board?
What is VOQUEZNA and how does it relate to PHAT's new board appointment?
What is Phathom Pharmaceuticals' (PHAT) main business focus?
